Using bioinformatic analysis, NDC80 was identified as a candidate prognostic biomarker for breast cancer survivors, which may be beneficial for evaluating adjuvant therapy response and cancer recurrence risk 16. The gene discussed is NDC80; the disease is breast carcinoma.